NEW YORK (GenomeWeb News) – The National Institute of Drug Abuse will give $10 million in 2010 to fund deep sequencing studies aimed at identifying SNP variants and structural variants that may affect addiction risk in samples that are known to have drug abuse phenotypes.
NIDA plans to issue up to four grants of as much as $2.5 million per year for five years for research that will explore particular pharmacogenomic regions already identified by genome-wide association studies and other means and which could benefit from deep next-generation sequencing and analysis.
The aim of the grant program is to support studies that will identify variants with rare to moderate frequencies that affect risk for addiction phenotypes. In addition to regions identified by GWAS, researchers may sequence candidate genes in individuals with extreme phenotypes, or other approaches that capitalize on genetic architecture.
The research may involve studies that will sequence replicated candidate regions associated with drug addiction; research into the genomic structure, including microdeletions and gene amplifications, across the human genome; integration of computational and experimental components, and comparative sequence analysis of candidate genes with model organisms; and identification of rare variants in genealogically defined populations using long-range phasing and haplotype imputation.
Applicants are encouraged to use the HapMap and 1000 Genomes projects, and they must use existing DNA samples that have been well characterized for addiction phenotypes.